Citeline and Norstella unite to provide life science clients with a complete suite of commercial and clinical solutions

The new organization will help life sciences companies accelerate their mission to improve strategic decision-making and facilitate access to treatment from the pipeline to patients.

June 28, 2022 – Norstella, an organization that helps life sciences companies overcome the complexity of the drug life cycle, and Citeline (formerly Pharma), a leading provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance. Intelligence) has agreed to merge the companies.

By integrating Norstella with Citeline, which consists of four prominent pharmaceutical solution providers: Evaluate, MMIT, Panalgo and The Dedham Group, the integrated company will provide intelligence and answers to its clients, making it a life sciences company. Is in a good position to help you reach your patients quickly. It is necessary from initial clinical development to commercialization. This move reflects the common goal of becoming an end-to-end solution provider and giving patients access to life-saving treatments.

Life sciences companies drive innovation towards more specialized therapies across all disease areas, including oncology and rare diseases, and bring the right medicines to market as patient populations become more targeted. How to, the latest innovations in real-world data and data science, and endpoints that take into account future payer reimbursement decisions, and ultimately how to reach patients in need.

“Our Northstar is to accelerate innovation and ensure that all patients receive the treatment they need,” said Mike Gallup, CEO of Norstella. “By integrating clinical and commercial intelligence with real-world data, the integrated enterprise is in a good position to fulfill its mission.”

Norstella and Citeline play a key role in helping pharmaceutical companies plan and overcome access barriers at all stages of the drug development life cycle, not just during clinical trials. Citeline’s solutions, including a portfolio of clinical trial products, provide insights to improve the speed and efficiency of clinical trials and mitigate risk. Today, the Citeline solution leverages Panalgo’s Instant Health Data Analytics platform, along with MMIT’s PAR data and other complementary Norstella data assets, to improve workflow and decision making, and ultimately to bring the product to market. To patients faster than ever.

“Our mission at Citeline is to accelerate patient treatment and patient connectivity to treatment. Ultimately, this fusion of commercial and clinical capabilities will advance our mission and lead pharmaceutical companies. The C Suite will be able to manage an unprecedented portfolio strategy, “said Ramsey Hashem, Citeline CEO and Jay Nadler, Executive Chair. “This involves deciding which drugs to market, what new indications to pursue, and how to target patients for clinical trials faster and at lower cost. And now, this involves understanding how to design clinical trials that generate the kind of data that payers need to make appropriate reimbursement and prescribing decisions. “

“It’s about making a difference in the lives of patients,” Gallup said. “This move will help us realize our vision of a more innovative and accessible healthcare market.”

The merger is expected to be completed in the second half of 2022, subject to customary completion conditions and regulatory approval.

Citeline and Norstella unite to provide life science clients with a complete suite of commercial and clinical solutions

Source link Citeline and Norstella unite to provide life science clients with a complete suite of commercial and clinical solutions

Related Articles

Back to top button